Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Aurora Cannabis (ACB) reaffirmed its fiscal 2027 Q2 guidance for sequential growth in quarterly net revenue and adjusted EBITDA, supported by recent acquisitions and international strength.
The accretive acquisition of Safari Flower Company, which received EU-GMP certification in July, is expected to add incremental net revenue and adjusted EBITDA and expand critical EU-GMP production capacity. Aurora highlights continued strong, profitable performance in Germany and Poland, including #1 market share by revenue in Poland, and ongoing UK expansion via the acquisitions of Internode Pharma and HAP Pharma Limited. The company reports a strong balance sheet with $149 million in cash as of June 30, 2026 and no debt, and plans continued investment in international markets to drive long-term medical cannabis growth.
Aurora Cannabis (ACB) responded on September 14, 2026 to Curaleaf Holdings' application to halt Aurora's at-the-market (ATM) share program, in the context of Curaleaf's ongoing hostile bid for Aurora.
Aurora states the ATM program was publicly announced in February 2026, over six months before Curaleaf's bid, and is a long-term capital tool to fund international growth, including recent UK acquisitions. Aurora reports that it is debt free with a strong cash position, while citing Curaleaf financial statements that show more than $1 billion of debt, including $500 million of senior secured notes at 11.5% interest as of June 30, 2026. Aurora's board and special committee have unanimously recommended that shareholders reject Curaleaf's hostile offer by taking no action and not tendering, and advise any shareholders who already tendered to withdraw their shares.
Aurora Cannabis (ACB) has appointed biopharmaceutical executive Faris El Refaie as Executive Vice President, Global Commercial, effective September 28, 2026. In this newly created role, he will oversee Aurora's global commercial function, including medical cannabis market strategy, portfolio alignment, customer engagement and commercial capability building across Canada, Europe, Australia, New Zealand and other international markets. El Refaie brings 25 years of experience from leadership roles at JAMP Pharma Group, GSK and AstraZeneca, with a background spanning innovative medicines, oncology, specialty care, vaccines and consumer healthcare.
Curaleaf (CURLF) responded on September 2, 2026 to Aurora Cannabis (ACB), reaffirming its takeover offer as the best value path for Aurora shareholders, highlighting a 45% premium to Aurora’s unaffected share price and a capped price of US$5.00 per share.
The company states the offer equates to a 110% ex‑cash premium and an implied CY2026E adjusted EBITDA multiple of 12.0x, over 68% above Canadian cannabis peers. It argues the US$5.00 cap still represents an 82% premium to Aurora’s 30‑day VWAP on August 10, 2026 and sits in the 92nd percentile of Canadian M&A premiums over 10 years. Curaleaf contrasts its own cash generation – US$50 million operating cash flow and US$17 million free cash flow in H1 2026, and US$145 million over the last twelve months – and access to US$500 million of senior secured notes, with Aurora’s negative operating cash flow, equity dilution of approximately 31% since 2020, and guidance for lower revenue and adjusted EBITDA by fiscal 2027.
Aurora Cannabis (ACB) announced that its board unanimously recommends shareholders reject Curaleaf Holdings’ unsolicited hostile takeover bid. The board advises investors to take no action, not tender their shares, and withdraw any shares already tendered.
Aurora states that it is debt free with approximately $149 million in cash, while Curaleaf carries over $1 billion in debt, based on each company’s June 30, 2026 financial statements. The company argues that the offer undervalues Aurora, does not provide an adequate change‑of‑control premium, and would give Curaleaf control over a portion of Aurora’s cash upon closing.
Aurora indicates that, based on the proposed exchange ratio, its shareholders would own about 7.7% of the combined company but hold only about 3.2% of the votes. The board reiterates confidence in Aurora’s standalone plan as a focused global medical cannabis business, highlighting its EU‑GMP manufacturing network, international footprint, and strong balance sheet.
Curaleaf (OTCQX: CURLF, TSX: CURA) issued a detailed response to recent public statements by Aurora Cannabis (TSX: ACB, NASDAQ: ACB) regarding Curaleaf's outstanding offer for Aurora. Curaleaf reiterates that it is offering Aurora shareholders a premium-valued transaction and the chance to participate in what it describes as a larger, stronger global cannabis platform, and says it remains willing to meet at any time to discuss terms.
According to Curaleaf, its proposal is based on Aurora’s latest published figures as of August 5, 2026, and it disputes Aurora’s description of the parties’ prior engagement. Curaleaf highlights, using figures it attributes to Aurora’s own disclosures, multi-year transformation costs exceeding C$400 million, a roughly 35% ACB share-price decline over the year to August 10, 2026 versus a 56% gain in Curaleaf’s shares, a June quarter adjusted EBITDA 63% lower than the March quarter (with C$5.1 million in add-backs), negative C$4.4 million cash flow from operations, and cultivation yields of 114 grams per plant versus more than double that level at Curaleaf. Curaleaf also notes that Aurora’s fiscal 2027 guidance points to lower revenue versus fiscal 2026, margin compression from about 64% to the mid‑to‑high‑50% range, and lower adjusted EBITDA, and states that Aurora’s share price rose materially after the offer announcement and has traded near the implied offer value, which Curaleaf views as support for the strategic rationale.
Aurora Cannabis (TSX/NASDAQ: ACB) responded to Curaleaf Holdings’ unsolicited hostile takeover bid, noting that a Special Committee of independent directors and the Board are reviewing the offer with financial and legal advisors. Shareholders are advised to take no action until a formal recommendation is issued; the offer remains open for at least 105 days from launch.
Aurora highlights its international medical cannabis strategy, reporting 17% year-over-year international net revenue growth in fiscal Q1 2027 and record global medical cannabis revenue and adjusted EBITDA in FY2026. The company reports three consecutive years of positive adjusted EBITDA, continued growth in Germany, leadership in Poland, and expanding presence in the UK through the acquisition of Internode Pharma and HAP Pharma. Aurora adds that EU-GMP production capacity has increased by more than 40% over five years, supporting global medical cannabis demand.
Aurora Cannabis (NASDAQ: ACB) announced the acquisition of Internode Pharma Limited, a licensed importer and wholesaler, and HAP Pharma Limited, a licensed pharmacy in Birmingham, UK. The deal gives Aurora direct ownership of a licensed import and distribution facility and a virtual pharmacy, extending its control from cultivation through to patient delivery in the UK medical cannabis market.
Aurora completed the transaction through a wholly owned subsidiary, indirectly buying 100% of both companies’ shares and paying selling shareholders GBP 2.1 million in cash, contingent on certain post-closing conditions. The company expects the acquisition to be accretive to future adjusted EBITDA through operational efficiencies, reduced reliance on third-party distributors and anticipated market share gains in the rapidly growing UK medical cannabis market.
Aurora Cannabis (TSX/NASDAQ: ACB) confirmed that Curaleaf Holdings has formally commenced an unsolicited take-over bid for all Aurora common shares. The Offer provides implied consideration of US$4.00 per share, made up of 0.3463 Curaleaf subordinate voting share plus US$0.75 in cash per Aurora share, and is subject to a value cap of US$5.00 per share, which Aurora notes is below the trading price reached on December 18, 2025.
The Offer must remain open for at least 105 days, giving Aurora shareholders until at least December 1, 2026 to respond. Aurora’s board has formed a special committee of independent directors to review the bid with external legal, financial, and advisory firms. Aurora is urging shareholders to take no action until the board issues a formal recommendation via a Directors’ Circular within 15 days of the bid.
Aurora Cannabis (NASDAQ: ACB; TSX: ACB) responded to Curaleaf Holdings’ stated intention to launch an unsolicited take-over bid for all Aurora common shares. The non-binding Proposal implies US$4.00 per Aurora share, composed of 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash, and includes a cap of US$5.00 per share. Aurora confirms prior approach letters from Curaleaf and notes the bid was not solicited. The Board will form a special committee of independent directors to review the Proposal alongside other strategic alternatives, and no decision has been made. Aurora continues normal operations and advises shareholders that no action is required at this time.